Vanguard Group’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-31,238
| Closed | -$22.8K | – | 4558 |
|
|
2023
Q4 | $22.8K | Buy |
31,238
+2,300
| +8% | +$1.95K | ﹤0.01% | 4436 |
|
|
2023
Q3 | $32.4K | Buy |
28,938
+2,692
| +10% | +$3.35K | ﹤0.01% | 4459 |
|
|
2023
Q2 | $35.4K | Hold |
26,246
| – | – | ﹤0.01% | 4492 |
|
|
2023
Q1 | $27.8K | Buy |
26,246
+9,300
| +55% | +$17.7K | ﹤0.01% | 4514 |
|
|
2022
Q4 | $39.8K | Hold |
16,946
| – | – | ﹤0.01% | 4464 |
|
|
2022
Q3 | $73K | Buy |
+16,946
| New | +$92.8K | ﹤0.01% | 4517 |
|
|
2022
Q2 | – | Sell |
-11,704
| Closed | -$101K | – | 4699 |
|
|
2022
Q1 | $101K | Sell |
11,704
-11,394
| -49% | -$108K | ﹤0.01% | 4593 |
|
|
2021
Q4 | $263K | Buy |
23,098
+10,313
| +81% | +$148K | ﹤0.01% | 4533 |
|
|
2021
Q3 | $223K | Buy |
12,785
+711
| +6% | +$11.7K | ﹤0.01% | 4477 |
|
|
2021
Q2 | $224K | Buy |
12,074
+528
| +5% | +$10.1K | ﹤0.01% | 4360 |
|
|
2021
Q1 | $287K | Buy |
+11,546
| New | +$346K | ﹤0.01% | 4213 |
|
|
2020
Q1 | – | Sell |
-115
| Closed | -$19K | – | 4151 |
|
|
2019
Q4 | $19K | Hold |
115
| – | – | ﹤0.01% | 4093 |
|
|
2019
Q3 | $44K | Hold |
115
| – | – | ﹤0.01% | 4092 |
|
|
2019
Q2 | $64K | Hold |
115
| – | – | ﹤0.01% | 4085 |
|
|
2019
Q1 | $133K | Hold |
115
| – | – | ﹤0.01% | 3983 |
|
|
2018
Q4 | $130K | Hold |
115
| – | – | ﹤0.01% | 3960 |
|
|
2018
Q3 | $174K | Buy |
115
+90
| +360% | +$133K | ﹤0.01% | 4021 |
|
|
2018
Q2 | $32K | Sell |
25
-21
| -46% | -$115K | ﹤0.01% | 4113 |
|
|
2018
Q1 | $463K | Buy |
46
+3
| +7% | +$33.6K | ﹤0.01% | 3800 |
|
|
2017
Q4 | $616K | Hold |
43
| – | – | ﹤0.01% | 3698 |
|
|
2017
Q3 | $1.2M | Sell |
43
-6
| -12% | -$184K | ﹤0.01% | 3543 |
|
|
2017
Q2 | $2.5M | Sell |
49
-11
| -18% | -$601K | ﹤0.01% | 3316 |
|
|
2017
Q1 | $4.55M | Hold |
60
| – | – | ﹤0.01% | 3087 |
|
|
2016
Q4 | $4.76M | Buy |
60
+1
| +2% | +$89.4K | ﹤0.01% | 3084 |
|
|
2016
Q3 | $7.46M | Buy |
59
+3
| +5% | +$374K | ﹤0.01% | 2816 |
|
|
2016
Q2 | $6.05M | Buy |
56
+4
| +8% | +$470K | ﹤0.01% | 2885 |
|
|
2016
Q1 | $6.85M | Buy |
52
+4
| +8% | +$429K | ﹤0.01% | 2805 |
|
|
2015
Q4 | $6.49M | Buy |
48
+1
| +2% | +$149K | ﹤0.01% | 2864 |
|
|
2015
Q3 | $7.57M | Buy |
47
+9
| +24% | +$2.1M | ﹤0.01% | 2756 |
|
|
2015
Q2 | $11.5M | Buy |
+38
| New | +$10M | ﹤0.01% | 2604 |
|
Other funds holding NVIV
Vanguard Group's NVIV Position: Q1 2024 in Review
Vanguard Group sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2024, closing a stake of 31,238 shares — an estimated $22.8K sold.
Vanguard Group first reported a position in NVIV in Q2 2015 and held it in 30 quarters. The position peaked at $11.5M in Q2 2015. 4 funds tracked by Wall St. Rank hold NVIV as of Q1 2024.
- Vanguard Group reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2024 after selling out during the quarter.
- Vanguard Group sold 31,238 InVivo Therapeutics Holdings Corp shares in Q1 2024, an estimated $22.8K.
- Vanguard Group first reported a position in InVivo Therapeutics Holdings Corp in Q2 2015 and held it in 30 quarters.
- Vanguard Group's InVivo Therapeutics Holdings Corp position peaked at $11.5M in Q2 2015.
- 4 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2024.
Based on Vanguard Group's 13F filing for Q1 2024, filed 10 May 2024.